Share
622 Posts.
lightbulb Created with Sketch. 156
clock Created with Sketch. 13/03/23
12:12
Share
Originally posted by TheAnalyst007:
↑
NEU just received approval for Trofinetide, the first ever treatment for Rett Syndrome (a rare disease that affects far fewer people than iAMD does).
Expand
I’m sure the NEU announcement should bring a bit of love to the sector! Definitely seems like EYE has a bit more going for it with a device (in the high growth MIGS market, CAGR 20%) that is already approved and a potential first ever treatment for a much more common disease $30m market cap ONLY Revenue generating ($15m LTM, 28% growth, new product that will drive significantly higher revenue growth for CY23) Exciting R&D pipeline —> seeking FDA approval for the first ever treatment for intermediate AMD (affecting 1 in 7 people and the leading cause of blindness)
(20min delay)